EXOZYMES INC (EXOZ) Fundamental Analysis & Valuation

NASDAQ:EXOZ • US4618741098

Current stock price

10.31 USD
-0.19 (-1.81%)
Last:

This EXOZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EXOZ Profitability Analysis

1.1 Basic Checks

  • In the past year EXOZ has reported negative net income.
  • In the past year EXOZ has reported a negative cash flow from operations.
  • In the past 5 years EXOZ always reported negative net income.
  • In the past 5 years EXOZ always reported negative operating cash flow.
EXOZ Yearly Net Income VS EBIT VS OCF VS FCFEXOZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

  • The Return On Assets of EXOZ (-153.37%) is worse than 84.30% of its industry peers.
  • EXOZ has a worse Return On Equity (-269.59%) than 73.45% of its industry peers.
Industry RankSector Rank
ROA -153.37%
ROE -269.59%
ROIC N/A
ROA(3y)-85.21%
ROA(5y)-71.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EXOZ Yearly ROA, ROE, ROICEXOZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EXOZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EXOZ Yearly Profit, Operating, Gross MarginsEXOZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. EXOZ Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EXOZ has more shares outstanding
  • The debt/assets ratio for EXOZ is higher compared to a year ago.
EXOZ Yearly Shares OutstandingEXOZ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 2M 4M 6M 8M
EXOZ Yearly Total Debt VS Total AssetsEXOZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • EXOZ has an Altman-Z score of 10.54. This indicates that EXOZ is financially healthy and has little risk of bankruptcy at the moment.
  • EXOZ has a better Altman-Z score (10.54) than 81.78% of its industry peers.
  • EXOZ has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • EXOZ has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: EXOZ outperforms 45.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 10.54
ROIC/WACCN/A
WACCN/A
EXOZ Yearly LT Debt VS Equity VS FCFEXOZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • EXOZ has a Current Ratio of 2.51. This indicates that EXOZ is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.51, EXOZ is not doing good in the industry: 69.77% of the companies in the same industry are doing better.
  • EXOZ has a Quick Ratio of 2.51. This indicates that EXOZ is financially healthy and has no problem in meeting its short term obligations.
  • EXOZ has a worse Quick ratio (2.51) than 68.02% of its industry peers.
Industry RankSector Rank
Current Ratio 2.51
Quick Ratio 2.51
EXOZ Yearly Current Assets VS Current LiabilitesEXOZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. EXOZ Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.00% over the past year.
EPS 1Y (TTM)26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. EXOZ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EXOZ. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXOZ Price Earnings VS Forward Price EarningsEXOZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXOZ Per share dataEXOZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EXOZ Dividend Analysis

5.1 Amount

  • No dividends for EXOZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXOZ Fundamentals: All Metrics, Ratios and Statistics

EXOZYMES INC

NASDAQ:EXOZ (4/23/2026, 8:06:12 PM)

10.31

-0.19 (-1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)N/A
Inst Owners0.74%
Inst Owner Change0%
Ins Owners24.59%
Ins Owner Change-0.1%
Market Cap87.43M
Revenue(TTM)N/A
Net Income(TTM)-9.16M
AnalystsN/A
Price TargetN/A
Short Float %0.43%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.74
P/tB 25.74
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -153.37%
ROE -269.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.21%
ROA(5y)-71.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.51
Quick Ratio 2.51
Altman-Z 10.54
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)117.97%
Cap/Depr(5y)238.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.77%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-63.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.56%
OCF growth 3YN/A
OCF growth 5YN/A

EXOZYMES INC / EXOZ Fundamental Analysis FAQ

What is the ChartMill fundamental rating of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a fundamental rating of 1 / 10 to EXOZ.


What is the valuation status of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a valuation rating of 0 / 10 to EXOZYMES INC (EXOZ). This can be considered as Overvalued.


How profitable is EXOZYMES INC (EXOZ) stock?

EXOZYMES INC (EXOZ) has a profitability rating of 0 / 10.